Eton Pharmaceuticals Aktie
WKN DE: A2N38G / ISIN: US29772L1089
30.04.2024 14:51:06
|
Eton Pharmaceuticals Announces NDA Submission For ET-400
(RTTNews) - Eton Pharmaceuticals (ETON) announced the submission of a New Drug Application to the FDA for approval of ET-400, Eton's proprietary patented formulation of hydrocortisone oral solution. The company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2025.
"We are confident that ET-400, once approved, and Alkindi Sprinkle can achieve potential combined peak sales of more than $50 million annually," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-400, which expires in 2043.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eton Pharmaceuticals Inc Registered Shsmehr Nachrichten
06.08.25 |
Ausblick: Eton Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
12.05.25 |
Ausblick: Eton Pharmaceuticals zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Eton Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Eton Pharmaceuticals Inc Registered Shs | 19,93 | 0,66% |
|